Climacteric[JOURNAL]
Sun
200 papers
The effects of repeat fractional CO laser for postmenopausal vaginal symptoms following unblinding from a double-blind RCT.
Li FG, Knapman BL, Nesbitt-Hawes E … +2 more , Deans R, Abbott J
Climacteric · 2025 Dec · PMID 40569021 · Publisher ↗
OBJECTIVE: This study aimed to explore the effects of blinding on patient-reported outcomes. METHOD: Findings from this prospective open-label extension study were compared to a previous double-blind sham-controlled rand...
OBJECTIVE: This study aimed to explore the effects of blinding on patient-reported outcomes. METHOD: Findings from this prospective open-label extension study were compared to a previous double-blind sham-controlled randomized trial. Women with any postmenopausal vaginal symptom previously receiving either active or sham vaginal fractional CO laser were recruited from the index randomized controlled trial (RCT), and underwent an active laser protocol. Symptom severity was assessed by co-primary outcomes of a visual analog scale (VAS) for overall and most bothersome symptom and the Vulvovaginal Symptom Questionnaire (VSQ) to 12 months. RESULTS: Of the 25 participants, there was a significant improvement in the co-primary outcomes at 6 months from baseline (mean difference: overall vaginal symptoms VAS, 22.0 [95% confidence interval (CI) -32.2, -11.8]; most bothersome symptom VAS, -22.1 [95% CI -36.7, -7.5]; VSQ, -2.2 [95% CI -3.8, -0.6]). At 12 months, there was significant improvement in most bothersome symptom VAS (-17.8 [95% CI -35.3, -0.3]) and VSQ (-2.3 [95% CI -3.9, -0.8]) scores. There was no significant difference in the post-treatment improvement of the co-primary outcomes at 6 and 12 months following open-label laser treatment, when compared to index RCT outcomes following active laser and sham laser treatment, respectively. CONCLUSION: Blinding in randomized trials is essential for correctly interpreting clinical outcomes using lasers for genitourinary symptoms of menopause.
Practices and challenges in the management of the menopause in the Asia-Pacific Menopause Federation.
Ang SB, Tan FCJH, Sugianto SRS … +14 more , Davison S, Yu Q, Terauchi M, Kim MR, Shah J, Nasreen SKZA, Ho CM, Sodnomdorj E, Siregar MFG, Hussain R, Gamilla MCZN, Chua Y, Tsai YC, Jaisamrarn U
Climacteric · 2025 Aug · PMID 40549652 · Publisher ↗
OBJECTIVES: The experiences and needs of women undergoing the menopausal transition vary widely amongst countries in the Asia-Pacific. Thus, practices and challenges amongst clinicians treating perimenopausal and menopau...
OBJECTIVES: The experiences and needs of women undergoing the menopausal transition vary widely amongst countries in the Asia-Pacific. Thus, practices and challenges amongst clinicians treating perimenopausal and menopausal women in the Asia-Pacific also vary. This study aims to characterize the diverse practices and challenges in managing the menopause across the Asia-Pacific. METHODS: Clinicians in the member organizations of the Asia-Pacific Menopause Federation were invited to participate in a questionnaire seeking information on their usual practices and the challenges faced in managing the menopause. RESULTS: A total of 39 clinicians from 14 countries in the Asia-Pacific Menopause Federation responded to the questionnaire. While there were similar practices in assessment, clinicians' preferences in prescribing menopausal hormonal therapy varied widely. Challenges they faced included cultural and literacy barriers amongst their patients, a lack of support for menopause care in their healthcare systems and limited availability of novel therapies. CONCLUSION: Practices in managing the menopause vary across the Asia-Pacific. Further research and governmental support are needed to establish consensus on managing the menopause and supporting midlife women's health issues in the Asia-Pacific.
Adjuvant treatment with tamoxifen for estrogen receptor-positive breast cancer and gynecological risks in premenopausal and perimenopausal women - a systematic review.
Plougmann Gislinge JI, Rubeck Petersen K, Borgquist S … +1 more , Ravn P
Climacteric · 2025 Dec · PMID 40539456 · Publisher ↗
OBJECTIVE: Tamoxifen (TMX) is known to increase the risk of endometrial cancer (EC) in postmenopausal women, but data on the effects in premenopausal and perimenopausal women remain inconsistent and not well illuminated....
OBJECTIVE: Tamoxifen (TMX) is known to increase the risk of endometrial cancer (EC) in postmenopausal women, but data on the effects in premenopausal and perimenopausal women remain inconsistent and not well illuminated. This study aimed to evaluate whether TMX increases the risks of gynecological symptoms and EC in premenopausal and perimenopausal women receiving adjuvant therapy for estrogen receptor-positive breast cancer. METHODS: Systematic searches in PubMed, Cochrane and Web Of Science yielded 319 relevant articles, of which 38 were analyzed after excluding duplicates and non-qualifying studies. The Oxford Criteria were used to ensure consistent evaluation before final inclusion. No meta-analysis was conducted due to study heterogeneity. RESULTS: Ten studies (two meta-analyses, one systematic review, four retrospective cohort studies, one retrospective comparative study, one prospective cohort study and one case-control study) were included. TMX was associated with an increased risk of EC in premenopausal and perimenopausal women (mean relative risk 2.25; standard deviation 0.9) compared to no treatment or treatment with raloxifene or aromatase inhibitors. Risk appeared in some studies to increase with treatment duration and persisted for ≥5 years post treatment. TMX also significantly increased the risk of gynecological symptoms, benign and premalignant endometrial pathology, intrauterine procedures and hysterectomy ( < 0.001). CONCLUSIONS: TMX seems to increase EC risk and significantly increase the risk of gynecological symptoms in premenopausal and perimenopausal women, with risk persisting years following treatment cessation. Healthcare professionals should counsel these women on potential risks and emphasize prompt evaluation of gynecological symptoms.
Menopause in low and middle-income countries: a scoping review of knowledge, symptoms and management.
Islam RM, Rana J, Katha S … +6 more , Hossain MA, Salekin SU, Chowdhury AT, Kabir A, Romero L, Davis SR
Climacteric · 2025 Jun · PMID 40536363 · Publisher ↗
OBJECTIVE: This study aimed to systematically map available evidence on menopause-related knowledge, symptoms and management in low and middle-income countries (LMICs) and identify critical gaps to inform research and po...
OBJECTIVE: This study aimed to systematically map available evidence on menopause-related knowledge, symptoms and management in low and middle-income countries (LMICs) and identify critical gaps to inform research and policy. METHODS: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Review (PRISMA-ScR) guidelines, the MEDLINE, EMBASE, CINAHL and Scopus databases were searched for studies published between 2000 and 2024. Eligible studies were those that reported on menopause-related knowledge, symptom prevalence or management in LMICs. Data were extracted and synthesised descriptively and thematically. RESULTS: From 10,758 records, 252 studies from 41 LMICs were included. Most were cross-sectional (85%) and relied on non-probability sampling (62%), with only 4% being nationally representative. Menopause classification methods were often inconsistent, with only 17.5% of studies using the Stages of Reproductive Aging Workshop (STRAW) +10 or World Health Organization (WHO) criteria. National-level data on age at menopause are lacking across all LMICs. The prevalences of vasomotor symptoms, joint pain and sexual concerns were comparable with high-income countries. However, data on the severity and burden of symptoms were scarce. Knowledge about menopause and menopausal hormone therapy (MHT) was poor, especially in low-income and rural settings. Cultural stigma, misconceptions and healthcare provider knowledge gaps contributed to low uptake of evidence-based menopause care. MHT use was consistently low, with women predominantly using traditional remedies. Provider hesitancy, lack of training and structural health system barriers were key limitations in service delivery. CONCLUSIONS: Despite a growing population of postmenopausal women, menopause remains a neglected health issue across LMICs. There is an urgent need to integrate menopause into reproductive and non-communicable disease policies, invest in provider education and ensure equitable access to evidence-based menopause care, including MHT, for women in LMICs.
Enhancing quality of life: addressing vulvovaginal atrophy and urinary tract symptoms.
Hirschberg AL
Climacteric · 2025 Aug · PMID 40531325 · Publisher ↗
About 50% of postmenopausal women experience symptoms of vulvovaginal atrophy (VVA) including vulvovaginal dryness, burning, itching and dyspareunia as a natural physiological consequence of hypoestrogenism. These sympto...
About 50% of postmenopausal women experience symptoms of vulvovaginal atrophy (VVA) including vulvovaginal dryness, burning, itching and dyspareunia as a natural physiological consequence of hypoestrogenism. These symptoms can have a major impact on quality of life and sexual function. VVA is a component of genitourinary syndrome of menopause, also associated with urinary tract problems such as frequent urination, urge incontinence and recurrent urinary tract infections. Vaginal low-dose estrogen is an effective treatment for symptoms of VVA, overactive bladder and urge incontinence, and prevents recurrent urinary tract infections. In contrast, systemic menopausal hormone therapy seems to worsen urinary incontinence. Women with breast cancer treated with aromatase inhibitors often have severe symptoms of VVA and urinary tract problems. Non-hormonal lubricants and moisturizers should be the first-line treatment in these patients. However, there is no evidence of increased cancer recurrence by low-dose vaginal estrogen in breast cancer survivors. When non-hormonal products are ineffective, low-dose vaginal estrogen could be considered in collaboration with the woman's oncologist. An individualized approach is required for the management of VVA and urinary tract symptoms. As VVA is a chronic condition, women should not be denied long-term use of vaginal estrogens if the treatment is of benefit to them.
Hormone therapy and insulin resistance in non-diabetic postmenopausal women: a systematic review and meta-analysis.
Li T, Jiang NS, Kaskey J … +2 more , Schnatz PF, Nudy M
Climacteric · 2025 Dec · PMID 40531213 · Full text
OBJECTIVE: Menopause increases the risk of insulin resistance and cardiometabolic diseases. This study summarizes the effects of hormone therapy (HT) on insulin resistance in non-diabetic postmenopausal women. METHOD: Th...
OBJECTIVE: Menopause increases the risk of insulin resistance and cardiometabolic diseases. This study summarizes the effects of hormone therapy (HT) on insulin resistance in non-diabetic postmenopausal women. METHOD: The study analyzed randomized controlled trials (1998-2024) that assessed the impact of HT on insulin resistance using homeostasis model assessment of insulin resistance (HOMA-IR) in non-diabetic postmenopausal women. Raw mean differences (RMDs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Subgroup analysis compared estrogen alone (E alone) and estrogen plus progestogen (E + P) to placebo. RESULTS: Seventeen randomized controlled trials with 5772 women (3644 on HT: E alone [ = 1259] or E + P [ = 2385]; 2128 on placebo) were included. The weighted mean (standard deviation) age was 56.91 (5.95) years, with treatment lasting 8 weeks to 3 years. HT significantly reduced HOMA-IR (RMD = -0.24 [-0.32 to -0.16], < 0.001, = 60.3%). Subgroup analysis showed reductions in both E alone (RMD = -0.42 [-0.55 to -0.29], < 0.001, = 35%) and E + P (RMD= -0.14 [-0.23 to -0.04], = 0.005, = 13.7%) compared to placebo. CONCLUSION: HT significantly lowers insulin resistance in healthy, non-diabetic postmenopausal women, with E alone yielding greater reductions than combination therapy.
Burden, trends and projections of low bone mineral density in premenopausal/postmenopausal women.
Liao J, Wang Y, Turson R … +1 more , Fang R
Climacteric · 2025 Dec · PMID 40531171 · Publisher ↗
OBJECTIVES: Low bone mineral density (LBMD) significantly contributes to global morbidity and mortality, especially in postmenopausal women. However, its burden in premenopausal women remains underrecognized. This study...
OBJECTIVES: Low bone mineral density (LBMD) significantly contributes to global morbidity and mortality, especially in postmenopausal women. However, its burden in premenopausal women remains underrecognized. This study evaluated the global burden, temporal trends and future projections of LBMD-related outcomes. METHODS: Data were obtained from the Global Burden of Disease 2021 dataset covering 204 countries. Premenopausal and postmenopausal women from 1990 to 2021 were included. Incidence, mortality and disability-adjusted life years (DALYs) were extracted, and age-standardized rates were calculated. The study explored demographic and epidemiologic changes, applied inequality indices and employed a Bayesian Markov chain Monte Carlo model to forecast trends through 2035. RESULTS: Between 1990 and 2021, LBMD-related mortality rose by 27.39% (95% uncertainty interval [UI] 16.83-39.69) among premenopausal women and 138.73% (95% UI 98.45-186.25) among postmenopausal women. In 2021, the postmenopausal age-standardized rate (27.92 per 100,000) was 63.5 times higher than that of premenopausal women (0.44 per 100,000). By 2035, although rates may decline, overall deaths and DALYs will likely increase due to population growth and aging. CONCLUSION: Despite decreasing standardized rates, the absolute burden of LBMD continues to grow. Early screening and targeted prevention, especially for postmenopausal and underrecognized premenopausal women, is crucial to lessen its global impact.
Menopause and aging in sub-Saharan Africa: a narrative review.
Matina SS, Cohen E, Mokwena K … +1 more , Mendenhall E
Climacteric · 2025 Jun · PMID 40525389 · Publisher ↗
Menopause is commonly viewed as a hormone deficiency and a risk factor for chronic illness, but it also represents a biological transition and profound social role change for women. This narrative review synthesises evid...
Menopause is commonly viewed as a hormone deficiency and a risk factor for chronic illness, but it also represents a biological transition and profound social role change for women. This narrative review synthesises evidence on how women in sub-Saharan Africa conceptualise and experience menopause and ageing, and examines how research has captured these dimensions. Databases including SCOPUS, Science Direct, Mendeley Data, Web of Science, PubMed, Medline African Medical Index, and the National Library of Medicine were searched using the terms 'menopause', 'ageing/aging' and 'sub-Saharan Africa'. Forty-two qualitative and quantitative studies in English and French were included. The review found that while many studies emphasise biological markers, symptoms, and the links between menopause and chronic disease, a significant number also highlight women's own interpretations of menopause as a social transition, sometimes associated with enhanced status and autonomy. In some contexts, menopause is linked to stigma or loss of femininity, while in others, it enables greater autonomy and decision-making power. Few women report awareness or acceptance of biomedical interventions such as menopause hormone therapy, tending to view menopause as a natural process rather than a medical condition. These findings underscore the importance of culturally sensitive public health interventions and clinical strategies that address both the biomedical and sociocultural dimensions of menopause, to promote healthy ageing and reduce the burden of chronic disease among women in sub-Saharan Africa.
Effect of hormone therapy on tryptophan metabolism and atherosclerosis among postmenopausal women.
Sriprasert I, Hilser JR, Kono N … +6 more , Karim R, Stanczyk FZ, Shoupe D, Hodis HN, Mack WJ, Allayee H
Climacteric · 2025 Dec · PMID 40512395 · Full text
OBJECTIVE: This study examined the effect of hormone therapy (HT) on tryptophan-kynurenine pathway metabolites and associations with atherosclerosis among postmenopausal women. METHODS: Eighty early postmenopausal partic...
OBJECTIVE: This study examined the effect of hormone therapy (HT) on tryptophan-kynurenine pathway metabolites and associations with atherosclerosis among postmenopausal women. METHODS: Eighty early postmenopausal participants from the Early versus Late Intervention Trial with Estradiol (40 each from HT vs. placebo) were selected for analysis. Tryptophan, -acetyltryptophan, kynurenine, kynurenic acid and -acetylkynurenine baseline and 36-month levels were measured by mass spectrometry. Mixed models tested HT effects on each metabolite, association of estradiol (E2) level with change in metabolite levels and association between change of metabolite with carotid artery intima-media thickness (CIMT) progression. RESULTS: Compared with placebo, HT significantly reduced kynurenic acid (mean change HT minus placebo -0.27; 95% confidence interval [CI] - 0.42, -0.12; = 0.0007) and -acetylkynurenine (-0.38; 95% CI -0.68, -0.08; = 0.04) levels. Reduction in kynurenic acid was inversely associated with higher E2 levels. Decreased CIMT progression was associated with lower kynurenic acid (0.0131 µm/year per unit; 95% CI 0.0049, 0.0212; = 0.002) and -acetylkynurenine (0.0061 µm/year per unit; 95% CI 0.0020, 0.0103; = 0.004) levels. CONCLUSIONS: Plasma tryptophan-kynurenine pathway metabolites were reduced by HT and these reduced metabolite levels were associated with decreased atherosclerosis progression. Reduction of kynurenic acid by HT was supported by its association with E2 levels, which may explain, in part, the reduction in atherosclerosis progression with HT in early postmenopausal women.
Menopausal symptoms among multi-ethnic working women in Malaysia.
Damodaran P, Ng BK, Azmi AH
Climacteric · 2025 Jun · PMID 40503911 · Publisher ↗
OBJECTIVE: This study investigated the impact of ethnicity, annual income and age on menopausal symptoms among working Malaysian women aged 40-60 years. METHOD: A population-based study was conducted among Malaysia's mul...
OBJECTIVE: This study investigated the impact of ethnicity, annual income and age on menopausal symptoms among working Malaysian women aged 40-60 years. METHOD: A population-based study was conducted among Malaysia's multi-ethnic women (Malay, Chinese, Indian and mixed ethnicity). A structured 20-question survey collected data on demographics (ethnicity, annual income and age) and symptom prevalence. A total of 1825 eligible responses were analyzed to assess associations between ethnicity, annual income, age and symptom burden. RESULTS: The most common symptoms were joint pain (34.6%), sleep disturbances (31.1%), brain fog (26.2%), mood swings (25.8%) and digestive issues (25.5%). Indian women reported the highest prevalence of symptoms and had a 2.9-fold higher likelihood of experiencing four or more symptoms compared to Chinese women. Women in higher annual income groups reported more symptoms than those in lower annual income groups. Symptoms such as joint pain and vaginal dryness increased with age, peaking in women aged 55-60 years. Mood swings were highest in women aged 45-49 years, while hot flushes, night sweats and sleep disturbances peaked at age 50-54 years. CONCLUSION: Menopausal symptoms vary by ethnicity, income and age. Individualized, culturally sensitive approaches are essential to reduce the health and economic burdens of menopause.
Psyche and menopause: embracing the (positive) flip side of the coin.
Vegni E, Borghi L
Climacteric · 2025 Oct · PMID 40497362 · Publisher ↗
While the biological processes of menopause are universal, individual experiences vary widely, shaped by psychological, social and cultural factors. Recent perspectives advocate for an empowerment-based model, emphasizin...
While the biological processes of menopause are universal, individual experiences vary widely, shaped by psychological, social and cultural factors. Recent perspectives advocate for an empowerment-based model, emphasizing the importance of incorporating both medical and psychological dimensions into menopause management. This contribution builds upon previous models and integrates a psychological framework that considers menopause as not only a time of loss but also a period of growth, self-realization and transformation. From a psychological perspective, menopause invites a redefinition of identity, with key psychological changes structured around two central dimensions: body-space and time perception. The transition away from the cyclical rhythms of fertility to a more stable bodily and temporal experience provides women with a grounding sense of self and fosters a deeper engagement with long-term goals. These changes, although potentially disorienting, represent a developmental opportunity for stabilization and growth. By embracing this broader understanding, clinicians and researchers can support women in thriving during and beyond this stage, moving beyond solely symptoms management and fostering a collaborative relationship with women navigating this transition. Implications for clinical practice of this approach are discussed, offering guidance on how clinicians can integrate psychological well-being into menopause care.
Safety of menopause hormone therapy in postmenopausal women at higher risk of venous thromboembolism: a systematic review.
Hicks A, Robson D, Tellis B … +3 more , Smith S, Dunkley S, Baber R
Climacteric · 2025 Oct · PMID 40488293 · Publisher ↗
OBJECTIVE: Studies have shown that oral estrogen with or without progestogen increases the risk of venous thromboembolism (VTE). Recent data suggest that transdermal estrogen confers little to no increased risk of VTE. T...
OBJECTIVE: Studies have shown that oral estrogen with or without progestogen increases the risk of venous thromboembolism (VTE). Recent data suggest that transdermal estrogen confers little to no increased risk of VTE. There is no systematic review that examines menopause hormone therapy (MHT) use in women with risk factors for VTE. This systematic review therefore aims to summarize the evidence in this population. METHOD: The OVID Medline, Embase, PubMed and CENTRAL online databases were searched. A total of 762 studies were screened and 10 were included in the study. RESULTS: Six studies were case-control studies, two were randomized controlled trials (RCTs), one was an RCT that contained a nested case-control study and one was a cohort study. Studies were heterogeneous in their definition of menopause, dose, form and route of administration of MHT, and the underlying VTE risk factor being assessed. In women with risk factors for VTE, transdermal estrogen conferred no increased risk of VTE. Oral estrogen alone has the next safest profile, and oral estrogen plus a progestogen conferred the highest increased risk of VTE. CONCLUSION: Transdermal MHT appears safe in women with risk factors for VTE. Oral MHT, notably oral estrogen plus a synthetic progestogen, does increase relative risk. More contemporary data are required to confirm these findings.
REDLINC: two decades of collaborative insights into menopause and women's health in Latin America.
Tserotas K, Blumel JE
Climacteric · 2025 Jun · PMID 40488286 · Publisher ↗
The Collaborative Group for Research of the Climacteric in Latin America (REDLINC) was established 20 years ago and comprises physicians who specialize in menopause medicine to acquire local information and understand th...
The Collaborative Group for Research of the Climacteric in Latin America (REDLINC) was established 20 years ago and comprises physicians who specialize in menopause medicine to acquire local information and understand the health needs of our population. Since then, 12 collaborative multinational studies have been conducted. Some of our most relevant results are the average age of menopause in Latin America (48.6 years), and the significant impact on quality of life, metabolic syndrome, sleep issues, sexual dysfunction, anxiety, depression, muscle pain, low muscle mass and mild cognitive decline. Also, we report variations in menopausal hormone therapy (MHT) prescriptions, noting that the tendency to prescribe is stronger among physicians themselves than toward patients. Finally, several factors contribute to the prevention, alleviation and treatment of menopausal changes in women, such as obesity control, exercise, higher education, utilization of MHT and seeking help from menopause practitioners. This article highlights the gathered information on Latin American women, which has been implemented for patients' better understanding. Physicians' awareness has grown, protocols have been adapted to accommodate our healthcare realities and patients are seeking menopause healthcare practitioners. International collaboration is key to the success of this project.
Understanding experiences and views of the menopause in Zimbabwe and South Africa: a qualitative study.
Drew S, Buwu N, Gregson CL … +3 more , Micklesfield LK, Ferrand RA, Gooberman-Hill R
Climacteric · 2025 Jun · PMID 40476307 · Publisher ↗
OBJECTIVE: Menopause experiences are diverse and vary by social and cultural contexts. This study explored midlife women's experiences and views about menopause in urban settings in Zimbabwe and South Africa to inform co...
OBJECTIVE: Menopause experiences are diverse and vary by social and cultural contexts. This study explored midlife women's experiences and views about menopause in urban settings in Zimbabwe and South Africa to inform co-production of supportive interventions. METHOD: Forty semi-structured interviews were conducted with women aged 40-60 years. Purposive sampling identified women, considering their age, comorbidities, HIV status and socioeconomic background. Data were audio-recorded, transcribed and analyzed thematically. RESULTS: Three inter-related themes were identified: loss and decline; uncertainty; and acceptance and growth. For some women, fertility was integral to their identity, without which they felt 'incomplete'. Several women described shock and confusion at their unanticipated experiences of bodily changes. Difficulties arose distinguishing menopause symptoms from other conditions, and women highlighted absence of information about symptom management. To gauge what was 'normal', women compared their experiences with those of trusted women. Some women in South Africa welcomed menopause as their transition to a respected elder; menopause meant freedom from menstruation and childbirth. Acceptance related to women's sense of whether they experienced menopause at 'the right time'. CONCLUSION: The study highlights similarities in women's menopausal experiences across Africa, as well as affirming the existence of wide and varied local views.
Prevalence of depressive symptoms during the menopausal transition in Türkiye: impact of symptom severity, aging anxiety and health-related quality of life.
Aslan B, Önal Ö
Climacteric · 2025 Oct · PMID 40464923 · Publisher ↗
OBJECTIVE: This research aimed to determine the prevalence of depressive symptoms during the menopausal transition (MT) among women in Türkiye and to examine the effects of menopausal symptom severity, aging anxiety, hea...
OBJECTIVE: This research aimed to determine the prevalence of depressive symptoms during the menopausal transition (MT) among women in Türkiye and to examine the effects of menopausal symptom severity, aging anxiety, health-related quality of life (HRQoL) and sociodemographic factors on these symptoms. METHODS: The cross-sectional study included 1146 women aged 45-55 years in the MT phase who voluntarily agreed to participate. The data were collected via a link containing survey questions on Google Forms, including sociodemographic information, health status, gynecological/obstetric history, menopause questions and the following scales: Perimenopausal Depression Scale, Menopause Rating Scale (MRS), Aging Anxiety Scale and Short Form Health Survey. RESULTS: The prevalence of depressive symptoms during the MT (≥20 points) was found to be 27.1% (95% confidence interval: 24.6-29.8), with 3.8% experiencing severe depression, 12.7% moderate depression and 10.6% mild depression. Binary multiple logistic regression analysis identified residence in the Eastern and Southeastern Anatolia regions, alcohol consumption, higher MRS scores and lower mental component levels as significant predictors of depressive symptoms during the MT. CONCLUSIONS: This study provides valuable data on the prevalence of depressive symptoms during the MT among perimenopausal women in Türkiye, offering insights for developing targeted strategies for at-risk groups.
Genetic insights into the causal associations between immune cells and ovarian aging in the European population.
Qi T, Zhao W, Chen E … +6 more , Zhong Y, Cao B, Huang Y, Yin L, Zhou J, Qian J
Climacteric · 2025 Oct · PMID 40464911 · Publisher ↗
OBJECTIVE: This study aimed to investigate the potential causal relationship between 731 immune cell traits and age at natural menopause (ANM), a measurable endpoint for ovarian aging. METHODS: Based on variant ANM data...
OBJECTIVE: This study aimed to investigate the potential causal relationship between 731 immune cell traits and age at natural menopause (ANM), a measurable endpoint for ovarian aging. METHODS: Based on variant ANM data from the ReproGen Consortium, two-sample Mendelian randomization (MR) analyses were conducted in a European population to identify significant immune cell traits associated with menopausal timing using inverse variance weighting (IVW) methods as the primary strategy. The study performed additional scrutiny to test the robustness of the significant associations via weighted median and MR-Egger as complementary methods, heterogeneity and pleiotropy analyses, the Steiger test and reverse MR for testing directionality, and leave-one-out analysis for biased and dominant variants. Replication analyses were also carried out using an independent dataset for ANM from UK Biobank. RESULTS: After false discovery rate (FDR) correction, 10 significant immune cell traits were identified, suggesting putative causal associations with menopausal timing. Six immunophenotypes were associated with earlier ANM including CD39 activated regulatory T cell (Treg) %activated Treg, NK% CD3 lymphocyte and CD27 on four B cell types (IgDCD38 B cell, memory B cell, unswitched memory B cell, switched memory B cell). Four immunophenotypes were associated with later ANM: CD39 resting Treg absolute count, HLA DR CD4 %lymphocyte, CD24 on IgDCD38 memory B cell and HVEM (Herpesvirus Entry Mediator, also named as TNFRSF14) on CD4 T cell. These results were validated in the replication dataset from UK Biobank. No reverse causation was found. CONCLUSION: This study demonstrates a causal relationship between 10 immune cell traits and menopausal timing, thereby expanding our knowledge about reproductive aging from the perspectives of inflammaging.
Awareness of menopause and menopause hormone therapy in India: perspectives of healthcare providers and consumers.
Meeta M, Guduru S, Tanvir T … +1 more , Madan A
Climacteric · 2025 Jun · PMID 40455559 · Publisher ↗
OBJECTIVE: This study was a dual-module approach that aimed to evaluate knowledge and concerns of healthcare providers (HCPs) about menopause hormone therapy (MHT) in under-resourced communities, and to understand the aw...
OBJECTIVE: This study was a dual-module approach that aimed to evaluate knowledge and concerns of healthcare providers (HCPs) about menopause hormone therapy (MHT) in under-resourced communities, and to understand the awareness and sources of information on menopause and MHT in these communities. METHODS: The cross-sectional survey study consisted of two modules: the population module was administered offline and followed the computer-aided personal interview methodology; and the HCP module was an online, self-administered survey. RESULTS: Out of 32,518 women surveyed from underprivileged communities, 50% were unaware of the effects of menopause, and 62% were unaware of the available treatment; if offered by the HCP, 48% were willing to take treatment. Responses from 1261 HCPs showed that systemic MHT was prescribed by 62.4% of HCPs and vaginal estrogen therapy by 86.0%. Although 95% of HCPs were aware of the indications, risks and benefits of MHT, 57% used alternative therapies as first-line therapy and 71% used them as an adjunct to MHT. CONCLUSIONS: There is a lack of awareness regarding the impact of menopause on health and on the use of MHT, and educational programs may encourage women to seek help. While HCPs are knowledgeable, hesitancy in the use of systemic MHT indicates the need for professional training programs to increase confidence in prescription writing.
Menopausal symptoms: what are the differences between the West and the East?
Tang R, Liu Q, Yu Q
Climacteric · 2025 Oct · PMID 40401541 · Publisher ↗
The characteristics of menopause symptoms exhibit considerable variation across different countries and regions. Understanding these variations is crucial for developing strategies to manage the menopausal symptoms speci...
The characteristics of menopause symptoms exhibit considerable variation across different countries and regions. Understanding these variations is crucial for developing strategies to manage the menopausal symptoms specific to each region. A comparative analysis of menopausal symptoms between the East and the West is presented, based on a review of the epidemiological literature and data. In the East, the age of menopause and the onset of the menopausal symptoms were observed to occur slightly earlier than in the West. The two most commonly reported menopausal symptoms in western countries are hot flushes and sleeplessness, whereas Asian women mostly report somatic symptoms. The reported prevalence of menopausal symptoms varies considerably and differs substantially between the studies. These variations may be related to research methods, sample size, ethnicity, culture, socioeconomic differences, menopausal status and other factors.
Genitourinary syndrome of menopause: a multicenter study from the Indian Midlife Registry.
Ashraf AB, Meeta M, Chitra AB … +13 more , Pahwa S, Shah J, Mohi M, Reddy G, Aggarwal K, Sarkari A, Sharma S, Jaiswal J, Shah J, Sen B, Unni J, Mane S, Desai J
Climacteric · 2025 Jun · PMID 40397455 · Publisher ↗
OBJECTIVE: This study aimed to investigate the prevalence and characteristics of genitourinary syndrome of menopause (GSM) in midlife women. METHODS: The cross-sectional study from the Indian Midlife Registry included wo...
OBJECTIVE: This study aimed to investigate the prevalence and characteristics of genitourinary syndrome of menopause (GSM) in midlife women. METHODS: The cross-sectional study from the Indian Midlife Registry included women aged >40 years attending outpatient clinics at multiple centers across India. Real-world data were collected on an Electronic Health Record platform. GSM was diagnosed in the presence of either two genitourinary or sexual symptoms or one symptom and a Vaginal Health Index (VHI) score of ≤15. RESULTS: A total of 1781 women, 826 perimenopausal and 955 postmenopausal, were included. The prevalence of GSM was 48.5%, and the most prevalent symptoms were lower urinary tract symptoms (LUTS) (38.2%) and vaginal dryness (26.4%). The VHI score was ≤15 in 42.1% of women. Based on logistic regression analysis, age ≥70 years, late postmenopause, low education, insomnia and other sleep problems were associated with higher odds of GSM. CONCLUSION: GSM is highly prevalent in Indian women. GSM remains under-recognized and undertreated. Sleep problems, advanced age, late postmenopause and low education significantly increase the odds. This study underscores the importance of routine screening for GSM, especially in those with sleep disturbances or LUTS in order to improve quality of life (QoL).
Obesity indices and cardiometabolic diseases in postmenopausal women in Ilorin, Nigeria.
Obalowu IA, Odeigah LO, Mohammed A … +3 more , Oyeleke OA, Odediji TT, Amin MF
Climacteric · 2025 Jun · PMID 40391498 · Publisher ↗
OBJECTIVE: Obesity is a known risk factor for the development of cardiometabolic diseases (CMD) globally. The study focus was finding the best predictor of CMD among the four anthropometric indices of obesity studied: bo...
OBJECTIVE: Obesity is a known risk factor for the development of cardiometabolic diseases (CMD) globally. The study focus was finding the best predictor of CMD among the four anthropometric indices of obesity studied: body mass index (BMI), waist to hip ratio (WHR), waist to height ratio (WHtR) and visceral adiposity index (VAI). METHOD: A total of 310 postmenopausal women participated in the study. Sociodemographic data, anthropometric measurements, serum high-density lipoprotein and serum triglycerides were taken for all participants. The receiver operating characteristic curve was used to detect the valid cut-off point for the VAI. RESULTS: The VAI cut-off point for diagnosing visceral adiposity dysfunction (VAD) in the study was >1.92. The prevalence of peripheral obesity in the study was 18.1%, while that of truncal obesity was 76.5% using the WHR and 81.9% using the WHtR. The prevalence of CMD in the study was 51.6% while that for VAD was 60.3%. The WHtR ( = 0.041) and the VAI ( < 0.001) had statistically significant associations with the presence of CMD among the participants but only the VAI was found to be a significant predictor of CMD. CONCLUSION: We recommend use of the VAI for CMD screening among postmenopausal women.
About
- Frequency
- Sun
- Papers found
- 200
- RSS feed
- Subscribe